STOCK TITAN
  1. Home
  2. Financials
  3. LONA
  4. EPS (Diluted)

LeonaBio (LONA) EPS by Year

LONA NASDAQ

LeonaBio, Inc. lost $24.70 per diluted share in fiscal year 2025. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters LeonaBio, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$24.70
Source SEC Filings Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

LONA EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY25FilingFY24FilingFY23FilingFY22FilingFY21FilingFY20FilingFY19Filing
EPS (Diluted)-$24.70-$25.19-$3.09n/m-$2.53n/m-$1.49-$1.67-$1.45

LONA EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'25FilingQ2'2510-QQ1'2510-QQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23Filing
EPS (Diluted)-$0.80-$1.73-$18.90-$1.68-$1.78-$2.34-$0.39n/m-$7.46-$0.70n/m-$0.69n/m-$0.71n/m-$0.87n/m

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More LeonaBio, Inc. financials

Frequently Asked Questions

LeonaBio, Inc. lost $24.70 per diluted share in fiscal year 2025.

Across the 7 fiscal years this page covers, LeonaBio, Inc. (LONA) diluted earnings per share went from -$1.45 in fiscal year 2019 to -$24.70 in fiscal year 2025.

LeonaBio, Inc. (LONA) reported -$0.80 in diluted earnings per share in Q2 2026.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what LeonaBio, Inc. (LONA) reported on that line in every period on record.